ALPINE

Shares of Oncomed Pharmaceuticals Inc (NASDAQ: OMED) plunged 42 percent during Monday's pre-market session after the company provided an update on its Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data...